Abciximab is indicated for:
Population group: both men and women, only adults (18 years old or older)
Abciximab is indicated as an adjunct to heparin and acetylsalicylic acid for the short-term (1-month) reduction of the risk of myocardial infarction, in patients with unstable angina, not responding to full conventional therapy who have been scheduled for percutaneous coronary intervention.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: both men and women, only adults (18 years old or older)
Abciximab is indicated as an adjunct to heparin and acetylsalicylic acid for the prevention of ischaemic cardiac complications in patients undergoing percutaneous coronary intervention (PCI: balloon angioplasty, atherectomy, and stent).
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Abciximab is contraindicated in the following cases: